Janssen Search
Search results
Nature Research Custom Media: Heading Cancer Off at the Pass
Nature Research Custom Media: Heading Cancer Off at the Pass Jun 10, 2020 Excepteur sint occaecat cupidatat non Cupidatat nesciunt neque porrosed quia non numquam eius velit Sed quia non numquam eius m Excepteur sint occaecat cupidatat non Excepteur sint ...
CHMP recommends RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) after failure of prior therapy
Jul 26, 2024 Patients with EGFR ex19del or EGFR L858R mutations, the most common EGFR mutations in NSCLC, currently face a poor prognosis and limited treatment options after disease progression on osimertinib 1, 2, 3, 4 In the MARIPOSA-2 study, ...
Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT® (amivantamab-vmjw)
Sep 10, 2024 United States Pre-medication regimen showed an infusion-related reaction rate of 22.5 percent with intravenous RYBREVANT ®, a three-fold reduction from 67.4 percent historically seen with standard IRR management SAN DIEGO, CA, September 10, ...
Robin L. Kumoluyi
ROBIN L. KUMOLUYI VICE PRESIDENT & CHIEF QUALITY OFFICER PHARMACEUTICALS JOHNSON & JOHNSON Robin L. Kumoluyi is Vice President and Chief Quality Officer, Johnson & Johnson, Pharmaceuticals. Robin also is a member of the Johnson & Johnson ...
Guide to Expanded Access
This first-of-its-kind Guide To Expanded Access includes country-specific information on the availability of Expanded Access (EA), also known as compassionate use or pre-approval access, for 28 European countries, as well as Canada. It also describes the ...
Toon Overstijns
Toon Overstijns is the Global Commercial Strategy Leader for the Infectious Diseases & Vaccines Therapeutic Area. Toon started his career in Janssen as Area Managing Director for Janssen Central and Eastern Europe. He later served for five years as ...
RYBREVANT®▼ (amivantamab) in combination with chemotherapy is the first therapy approved by the European Commission for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations
Jun 28, 2024 Approval is supported by the Phase 3 PAPILLON study, which showed amivantamab plus chemotherapy significantly reduced the risk of disease progression or death by 60 percent compared to chemotherapy alone 1 BEERSE, BELGIUM (28 June 2024) – ...
One Size Fits Not: The "E's" of Accessible Transformational Medicines for Those Living with Rare Diseases
One Size Fits Not: The "E's" of Accessible Transformational Medicines for Those Living with Rare Diseases Did you know that approximately 300 million people worldwide are living with one of the 6,000+ rare diseases, most of which have no ...
RYBREVANT® (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancer
Sep 19, 2024 United States Approval based on compelling safety and efficacy from the Phase 3 MARIPOSA-2 study, marking the third new indication for RYBREVANT ® this year, with four indications overall RARITAN, New Jersey (September 19, 2024) – Johnson ...
Focused on Hepatitis C Treatment & Prevention
Article Type: Infectious Diseases & Vaccines Hepatitis B Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). It is, like hepatitis C (HCV), a major global health problem and significant burden on those ...